MAYO CLINIC LABORATORIES

NEW TEST

Notification Date: August 24, 2021
Effective Date: August 31, 2021

Bivalirudin, Ecarin, Plasma

Test ID: BIVAL

Useful for:
Monitoring of bivalirudin therapy for patients with prolonged baseline activated partial thromboplastin time

Ordering Guidance:
This test measures bivalirudin only. For measurement of argatroban direct thrombin inhibitor, order ARGAT/Argatroban, Ecarin, Plasma. For measurement of dabigatran direct thrombin inhibitor, order DABIE/Dabigatran, Ecarin, Plasma.

This test is **not indicated for** monitoring low molecular weight heparin (LMWH), unfractionated heparin (UFH), or oral direct anti-Xa inhibitors (eg, apixaban, rivaroxaban, edoxaban). For monitoring oral direct anti-Xa inhibitors, see APIXA/Apixaban, Anti-Xa, Plasma; EDOXA/Edoxaban, Anti-Xa, Plasma, or RIVAR/Rivaroxaban, Anti-Xa, Plasma.

Methods:
Chromogenic

Reference Values:
<0.10 mcg/mL

Specimen Requirements:

Supplies:	Aliquot Tube, 5 mL (T465)
Specimen Type:	Platelet-poor plasma
Collection Container/Tube:	Light-blue top (3.2% sodium citrate)
Submission Container/Tube:	Plastic vial (polypropylene preferred)
Specimen Volume:	1 mL
Collection Instructions:	1. Specimen should be collected 2 hours after initiation of continuous infusion of bivalirudin. 2. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing in Special Instructions. 3. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.

4. Aliquot plasma into a plastic vial leaving 0.25 mL in the bottom of centrifuged vial.
5. Freeze plasma immediately (no longer than 4 hours after collection) at -20 degrees C or, ideally, < or =-40 degrees C.

Minimum Volume: 0.5 mL

Additional Information:

1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.
2. Each coagulation assay requested should have its own vial.

Specimen Stability Information:

Specimen Type	Temperature	Time
Plasma Na Cit	Frozen	42 days

Cautions:

The recommended monitoring per product guidelines is with the activated partial thromboplastin time ratio, routine monitoring of bivalirudin drug levels is not indicated.

Bivalirudin concentration may be affected by drug interactions, liver, and renal disease.

Marked presence of hemolysis or bilirubin in the sample could falsely decrease bivalirudin levels. Marked presence of lipemia in the sample could falsely increase bivalirudin levels.

CPT Code:

80299

Day(s) Performed: Monday through Friday

Report Available: 1 to 3 days

Questions

Contact Bonnie Meyers, Laboratory Technologist Resource Coordinator at 800-533-1710.